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 Over the last decade, the increased understanding of the molecular basis of cancer 
has resulted in the development of a wide range of effective targeted therapies which has 
expanded the armamentarium of active drugs available to the oncologist.  Trastuzumab is 
the first of this new generation to be successfully applied in breast cancer and it now plays 
an important part in the management of metastatic and early breast cancer.  The 
introduction of Trastuzumab has been heralded as a successful example of modern “bench 
to bedside” development – from experimental models to translational experiments to clinical 
trials in the metastatic then adjuvant setting.  This process has been made possible by 
worldwide collaboration between laboratory scientists, the pharmaceutical industry and 
clinical trialists.   
The HER-2/neu (HER2) oncogene, also called c-erbB2, was discovered in the 1980’s and is 
a member of the erbB-like oncogene family.  It is related to, but distinct from, the epidermal 
growth factor receptor (EGFR) and shares a role in the regulation of cell proliferation. HER2 
is over-expressed in 15-30% of breast cancers and carries an adverse prognosis.(1, 2)  
HER2 cell surface protein over-expression is usually caused by amplification of the HER2 
gene.  (3, 4)  HER2 positive breast cancers represent one end of a spectrum of increasingly 
defined breast cancer subtypes, characterised by a high risk of recurrence and metastasis 
and reduced overall survival.   
Trastuzumab is a recombinant humanised monoclonal antibody (IgG) directed against the 
HER2 extracellular domain.  It is made with the hyper-variable antigen binding regions of a 
potent murine anti-HER2 monoclonal antibody grafted into a human IgG.  Its exact 
mechanism of action remains unclear and appears to differ in vivo compared to in vitro.  
Whether or not Trastuzumab induces HER2 receptor down-regulation remains a matter of 
controversy.  It may act by blocking HER2 receptor cleavage, inhibiting intracellular 
signalling pathways or even by anti-angiogenesis effects. (5)  It is clear that its action is not 
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only cytostatic but also cytotoxic and this may be in part due to recruitment of the immune 
system by antibody dependent cell mediated cytotoxicity.(6)  In addition to its direct 
mechanism of action, a theoretical synergy with chemotherapy may be important.   
Standardised selection of the correct population who benefit from Trastuzumab therapy is 
vital and has been the subject of ongoing development.  Guidelines are now well established 
at an international level that define HER2 over-expression (HER2 “positivity”) and thus 
predict a high chance of sensitivity to Trastuzumab.(7)  Algorithms use a mixture of 
immunohistochemistry (IHC) to measure the level of HER2 protein at the cell surface, and in-
situ hybridisation (FISH) to look for gene amplification.  FISH is widely held as the gold 
standard not just because there is a good correlation between DNA copy number and 
protein levels, but also because routine fixation processes mean that protein levels as 
measured by IHC may not always be an accurate indicator of the level in vivo in the patient.   
Trastuzumab in metastatic breast cancer 
 
As a single agent Trastuzumab can produce response rates up to 35% in selected 
metastatic breast cancer patients. (8, 9)   In vitro demonstration of additive or synergistic 
activity with a number of active chemotherapy drugs led to early clinical development in 
combination with chemotherapy. (10)  Landmark phase II and phase III trials reported 
response rates of 50-84% using Trastuzumab in combination with standard chemotherapy 
(paclitaxel, docetaxel or doxorubicin, and cyclophosphamide combinations) and 
demonstrated improvement in time to progression, duration of response and survival 
compared with the same chemotherapy alone as therapy for metastatic breast cancer over-
expressing HER2.(11-13)  Although combinations with a taxane or anthracycline were 
efficacious, anthracycline containing regimens produced unexpected and limiting 
cardiotoxicity.   
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Trastuzumab after progression? 
Trastuzumab has clearly revolutionised treatment for HER2 positive patients, however, half 
of the patients still have non-responding tumours and disease progression occurs within 1 
year in the majority of cases.  It remains uncertain whether further Trastuzumab either in 
combination with further chemotherapy or as a single agent is worthwhile.  It is also unknown 
whether retreatment on relapse is useful for patients who were treated with adjuvant 
Trastuzumab. Current guidelines do not recommend further treatment options after 
progression on Trastuzumab. (14)   There is, however, emerging evidence suggesting 
efficacy with further anti-HER2 therapy and many clinicians will continue Trastuzumab after 
progression.  Continuing Trastuzumab after cancer progression is undoubtedly an attractive 
option for patients and their treating oncologist due to low toxicity and lack of established 
alternatives. The implications for those funding healthcare are however significant, with the 
costs of trastuzumab and its administration at around Euro 40,000 (£32,000) for 1 year of 
treatment.(15) 
 
Initially the practise of continuing Trastuzumab after progression was based on preclinical 
studies that suggested Trastuzumab can slow down tumour growth in the presence of 
disease progression.   Clinical evidence that does exist is largely derived from retrospective 
studies and includes an extension trial to the pivotal phase III trial testing Trastuzumab in 
combination with first line palliative chemotherapy.  They suggest a reasonable safety and 
cardiotoxicity profile with continued treatment(16-18) and responses are at least as good 
when combined with second line chemotherapy compared to historical controls.(19-21)  A 
prospective observational database has been set up by Genentech with the hope of adding 
to this information. (22)  
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More convincing data comes from the randomised trial GBG26/TBP which set out to 
compare capecitabine with or without trastuzumab in patients who had progressed or 
relapsed after any prior trastuzumab treatment.  This was closed early on the 
recommendation of the IDMC after recruiting 156 patients.  The final analysis recently 
reported statistically significant advantages for the combination arm with increased response 
rates and mean TTP of 5.6 vs 8.2 months (p=0.034).  This is the strongest evidence to date 
supporting the role for continuing trastuzumab therapy in this situation. (23) 
 
The small molecule Lapatinib acts by inhibiting the receptor tyrosine kinase activity of HER2 
and also the EGFR (ErbB1) receptor.  A pivotal trial randomised between Capecitabine 
monotherapy and Capecitabine in combination with Lapatinib in patients who had been 
previously treated with Trastuzumab.  Recently published interim results reported a 
statistically significant improvement in the primary endpoint of time to progression (HR 0.57 
(95% confidence intervals 0.43 – 0.770, p=0.00013, medians of 4.3 months versus 6.2 
months respectively).  This demonstrated efficacy has led to approval for use in the US, EU 
and Switzerland. (24, 25)    
 
Both of these studies support ongoing anti-HER2 therapy in combination with Capecitabine 
in patients with progressive cancer after Trastuzumab. The level of benefit though does not 
appear as great as that seen when Trastuzumab was combined with anthracyclines or 
taxanes, and therefore there does remain some uncertainty as to the true level of benefit 
from continued HER2 blockade.  Importantly, they only provide evidence for patients pre-
treated with anthracyclines, taxanes and trastuzumab.  There remains no definitive evidence 
guiding the use of anti-HER2 therapy in other patient groups.  In particular there is no proof 
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that continuing Trastuzumab as a single agent is efficacious in this situation.  There remains 
much uncertainty which clearly still needs to be addressed by good quality adequately 
powered trials.   Prospective randomized trials called THOR (Italian) and PANDORA 
(multinational) are attempting to address this need – comparing second line chemotherapy 
with or without continued Trastuzumab – but these types of studies have always been 
difficult to recruit to, due in part to the expectation that continued anti-HER2 therapy is of 
benefit. 
 
Ultimately we need to further develop our understanding of the mechanisms by which 
tumours develop resistance to Trastuzumab if they are to be overcome.  Proposed 
mechanisms are numerous and varied but include increased cell signalling (PTEN loss, 
increased AKT activity),  alternative cell signalling mediated by EGFR family pathways (TGF-
a over-expression, neuregulin over-expression) and alternative cell signalling mediated by 
different pathways (VEGF over-expression, IGF1R over-expression).(5) In particular, when 
considering the potential benefit of an intracellular signalling blockade with small molecules 
such as Lapatinib, is the possible relevance of the truncated HER2 receptor, p95, which 
results in constitutive activation and no extra-cellular target to which an antibody such as 
Trastuzumab can bind. (26)  In addition to Lapatinib, other agents at an earlier stage of 
development are also showing promise.  Pertuzumab is a monoclonal antibody similar to 
Trastuzumab which targets a different region of the HER2 receptor. It has demonstrated 
activity in early phase trials when added to Trastuzumab for patients with disease 
progressing on Trastuzumab therapy, which incidentally provides further evidence of 
retained tumour sensitivity to anti-HER2 therapy even though resistance to Trastuzumab has 
developed.(27)   Gefitinib, a small molecule tyrosine kinase inhibitor (TKI) acting against 
ErbB1 has also been tested, but has failed to demonstrate a significant clinical effect when 
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used in combination with Trastuzumab.(28)  Another agent KOS-953 (17-AAG) inhibits the 
activity of heat shock protein 90 resulting in degradation and reduced expression of the 
HER2 receptor and has also produced responses in an early report from a phase II 
study.(29)  
 
Recent enthusiasm has also focused on the association between vascular endothelial 
growth factor receptor (VEGFR) and HER2 expression in breast tumours.(30)   Evidence 
suggests that VEGFR expression is linked to HER2 signalling and over-expression of HER2 
results in induction of VEGFR.(31)   Hence Trastuzumab is currently under evaluation in 
combination with Bevacizumab, an antibody directed against VEGF.  An impressive 
response rate of 46% was seen in a phase II trial testing this combination,(32) although 
concerns exist surrounding the potential combined cardiotoxicity of these two drugs.  
Pazopanib is a small molecule multi-targeted TKI which also inhibits VEGF and has recently 
demonstrated tolerability and activity when tested in combination with Lapatinib in a phase II 
trial. (33)    
 
It is now well recognised that HER2 positive breast cancer has a high rate of CNS 
involvement, and cerebral metastasis as the site of progression after Trastuzumab is 
unexpectedly common.(34-37)  The particular challenge facing us now is how best to control 
this disease, particularly when presenting in the setting of responding extra-cranial 
metastasis.(38)  Trastuzumab does not appear to efficiently cross the blood brain barrier, 
and so it is unclear if the current practise of local CNS therapy and continued Trastuzumab 
is optimal.  Although early data suggests that Lapatinib may play a role in controlling CNS 
disease(39), it is not known if switching to this agent would be of any advantage.   
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Adjuvant Trastuzumab 
The clear benefit of using Trastuzumab in patients with advanced HER2 positive breast 
cancer quickly led to the initiation of a series of large trials testing the hypothesis that the use 
of Trastuzumab in HER2 over-expressing early breast cancer could improve disease-free 
survival. Four large and two smaller trials have all now reported, and all but one has shown a 
benefit with the use of Trastuzumab in addition to adjuvant chemotherapy in both disease 
free survival and overall survival (table 1).  In fact Trastuzumab is the first monoclonal 
antibody to produce a survival advantage when used as adjuvant therapy.  Altogether these 
trials include more than 13,000 patients and provide a firm evidence base supporting its use 
in this setting.  The only trial not to show a clear benefit was the smaller PACS04 trial, (40) 
where the patients randomised to Trastuzumab, as in the FINHER trial (vide infra) were a 
subset of patients in a larger trial whose primary objective was a chemotherapy question. 
Thus, although there is little doubt for the role of adjuvant Trastuzumab, the differing designs 
of these trials leave many questions as to the optimum timing and duration of its use.   
 
Three North American studies (table 1) – the North Central Cancer Treatment Group 
(NCCTG) Intergroup N9831, the National Surgical Adjuvant Breast and Bowel Project 
(NSABP) B-31 and the Breast Cancer International Research Group (BCIRG) 006 trials 
based their design on data from trials in metastatic breast cancer using a taxane-
Trastuzumab combination.  Using a standard sequence of anthracycline followed by taxane, 
they added Trastuzumab to the taxane, continuing to a year in total. The similar designs of 
N9831 and B-31 led to the joint analysis of their combined data. (41-43)   The HERceptin 
Adjuvant (HERA) trial recruited from most of the rest of the world.  This tested the addition of 
one or two years of trastuzumab given as a single agent after completion of standard 
chemotherapy and radiotherapy. (44)   
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Table 1.  Large adjuvant trastuzumab trials 
 
N9831 / B-31 (42) BCIRG 006 (45) HERA (46) 
    
Chemotherapy 
doses 
AC = doxirubicin 60mg/m2 
cyclophosphamide 600mg/m2 
B-31: paclitaxel 175mg/m2 3 wkly x4 
or 80mg/m2 wkly x12 
N9831: paclitaxel 80mg/m2 wkly x12 
AC = doxirubicin 60mg/m2  
cyclophosphamide 600mg/m2 
TC = docetaxel (T) 75mg/m2 
carboplatin AUC 6 
Chemo = standard chemotherapy 
from a permitted list 
Trastuzumab 
doses 
4mg/kg loading dose 
2mg/kg weekly 
4mg/kg loading dose 
2mg/kg weekly 
8 mg/kg loading dose 
6 mg/kg 3 weekly 
Patient No. 3,969 3,222 3,401 (no trastuzumab and 1 
year arms) 
Median follow up 2.9 years 3 years 2 years 
Disease Free 
Survival  
73% vs. 86% at 4 years 
  (HR 0.49 [95 % confidence 
  interval (CI) 0.41 to 0.58]) 
AC-T 77%  at 4 years 
AC-TH 83%  at 4 years 
  (HR 0.61 [95% CI 0.48-0.76]) 
TCH 82% at 4 years 
   (HR 0.67 [95% CI 0.54-0.83]) 
74% vs. 81% at 3 years 
  (HR 0·64 [95% CI 0·54–0·76]) 
Overall Survival* 89% vs. 93% at 4 years 
  (HR 0.63 [95% CI 0.49 to 0.81]) 
AC-T 86%  at 4 years 
AC-TH 92%  at 4 years 
  (HR 0.59 [95% CI 0.42-0.85]) 
TCH 91% at 4 years 
   (HR 0.66 [95% CI 0.47-0.93]) 
92% vs. 90% at 3 years 
 (HR 0·66 [95% CI 0·47–0·91]) 
 
 
   
 
AC 
AC Paclitaxel 
 Paclitaxel 
Trastuzumab (H)  x 
1 year 
 
 Trastuzumab x 2 
years 
Trastuzumab x 1 
ye r 
Observation Chemo 
Chemo 
Chemo 
A
C A
C  Docetaxel Carboplatin  (TC) 
Trastuzumab x 1 
year 
 
Docetaxel 
Trastuzumab x 1 
year 
 
Docetaxel  
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Early reporting of trials led to initial concerns over data immaturity – perhaps no survival 
advantage would be seen? (47)  In fact the combined analysis of the two US trials N9831 
and NSABP B-31 reported a 33% improvement in survival after a median follow-up of two 
years.  Analysis of the HERA trial also at a median 2 years in 2006 saw a similar 34% 
improvement in overall survival. (46)   
 
The duration of treatment with Trastuzumab varies hugely between trials from 9 weeks to 2 
years.  One year of treatment, starting either with the taxane component of chemotherapy, or 
after chemotherapy, has been widely adopted as standard treatment across the world.  This 
treatment duration remains arbitrary at present but will be addressed in due course with the 
maturation of data from the third arm of the HERA trial.  This has not yet been released by 
the IDMC, but will allow us to compare 2 years to 1 year of Trastuzumab after 
chemotherapy.    
 
Researchers in Finland have added a new dimension to the debate with the publication of 
the FinHER trial.  231 women with HER2 positive tumours were identified within a larger 
adjuvant chemotherapy study.  They were randomised to treatment with or without 
Trastuzumab immediately after surgery concomitantly with the non-anthracycline part of their 
chemotherapy.  3-year recurrence-free survival was better in those who received 
Trastuzumab (89 percent vs. 78 percent; P=0.01) with a halving of the risk of recurrence 
achieved with only nine weeks Trastuzumab.  It resulted in women with HER2 positive 
breast cancer having the same prognosis as those with HER2 negative breast cancer in the 
same study. (48)   
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The FINHER data suggest a shorter duration could be just as effective as the longer 
durations tested in other trials.  It is perhaps no surprise that in both the UK and France, it is 
government money that supports two similar trials with a planned joint analysis to address 
this question. In the UK the Health Technology Assessment have funded a trial called 
Persephone which tests a shorter duration of Trastuzumab, comparing 1 year to 6 months of 
treatment after chemotherapy.  Detailed health economic data collection within Persephone 
will add a wealth of information to the ongoing debate surrounding the cost of new expensive 
adjuvant drug treatments. The PHARE trial in France, sponsored by Institut National de 
Cancer, follows a very similar design, and having opened earlier has already recruited over 
1,800 patients at 12 months which represents over half of its targeted accrual.  In addition, 
another trial from Finland, SOLD, is comparing the 9 week schedule used in FINHER with a 
full year’s post-op trastuzumab as used in the HERA trial.  This trial is similar in concept to a 
small randomised phase II study from ECOG, E2198.(49)  Whilst the trial was designed to 
address a safety, not an efficacy question, it included a very similar number of HER2 +ve 
patients as FinHER, and the 5-year outcome data from this study suggests little additional 
benefit from the maintenance Trastuzumab after completion of adjuvant chemotherapy plus 
Trastuzumab.  
 
An equally important, and perhaps more challenging, question addresses the optimal timing 
of Trastuzumab in relation to chemotherapy. Preclinical experiments suggest that concurrent 
administration is necessary to produce cytotoxicity, whereas sequential administration may 
be, at best, cytostatic.(50)  Administration with the taxane portion of accepted anthracycline-
taxane sequences is possible and efficacious, but trials have produced conflicting results 
between this and consecutive treatment.  The N9831 trial had a third arm where 
Trastuzumab was given for one year, starting after chemotherapy.  In the early analysis of 
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N9831 this arm appeared much less effective, in contrast to the HERA trial where it almost 
halves the rate of recurrence. It is interesting to note that in the HERA trial, the 26% of 
patients who received taxane-based chemotherapy had an apparently lower benefit from the 
subsequent year’s Trastuzumab.  However, neither of these data have been updated, so 
one cannot be sure that it is more effective to commence the Trastuzumab with the taxane, 
and this has the added disadvantage of starting the treatment only 3 weeks after a dose of 
anthracyclines.  Indirect comparisons of the cardiac toxicity data between the two 
approaches suggests a lower rate of cardiac toxicity when the Trastuzumab is given further 
away from the last anthracycline dose. 
 
The main barrier to concurrent administration of Trastuzumab and chemotherapy is the high 
risk of cardiotoxicity with an anthracycline-Trastuzumab combination.(12)  The novel 
schedule of platinum-taxane-Trastuzumab suggested strong synergy in pre-clinical studies 
and with efficacy being confirmed in metastatic breast cancer patients. (51).  Therefore the 
BCIRG006 included a third non-anthracycline containing arm aiming to reduce cardiac 
toxicity and build on preclinical data.  This proved to be almost as effective and definitely 
less cardiotoxic compared to the anthracycline containing arms.  Many argue that this is the 
most pragmatic treatment strategy in light of the absence of data confirming long term 
cardiac safety with the use of both an anthracycline and a taxane in the adjuvant treatment 
schedule.  There is, however, convincing evidence suggesting that patients with HER2 
positive tumours derive particular benefit from anthracyclines compared to patients with 
HER2 negative tumours.(52-54)  Although this benefit may only be seen then HER2 is co-
amplified with topoisomerase II,(55) this is hard to ignore.  One potential strategy for 
minimising cardiotoxicity with anthracycline-Trastuzumab combinations may by the use of 
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liposomal doxorubicin and this topic has been recently reviewed in detail by Rayson et al. 
(56)   
Future Directions 
Perhaps a next step required to fully integrate Trastuzumab into the curative treatment 
algorithm for breast cancer patients is to fully evaluate its role as neo-adjuvant therapy and 
attempts are now being made to extend the benefit seen with adjuvant Trastuzumab as neo-
adjuvant treatment.  The MD Anderson centre conducted a randomised trial where patients 
either received Trastuzumab or not, concurrently with neo-adjuvant chemotherapy. The 
study was stopped prematurely after only 42 patients had been enrolled, because a 
significantly increased rate of pathological complete response was seen (43% vs 23%; 
p=0.002).(57)  An interim analysis of the NOAH trial has recently been presented.  This 
larger study demonstrated that pathologically complete response was doubled when 
Trastuzumab was added to neo-adjuvant chemotherapy for HER2-positive breast cancer 
(43% versus 22%, P=0.002, n = 228) thus paralleling the adjuvant benefit. (58)  Both of 
these studies included concurrent use of Trastuzumab with the anthracycline epirubicin, and 
reported acceptable cardiac toxicity.   
 
Regarding the role of Trastuzumab in the 45-50% patients(44) with HER2 positive tumours 
co-expressing HER2 and the oestrogen receptor (ER),  pre-clinical evidence supports an 
interaction between their dependant signalling pathways.(59)  This is important because of 
the relative resistance of HER2 positive tumours to endocrine therapy. The TANDEM trial 
looking at this patient population demonstrated improved PFS with Anastrozole plus 
Trastuzumab over Anastrozole alone (median 4.8 vs 2.4 months, p=0.0016).(60) Given the 
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rapid disease progression in these patients, the question is raised as to whether these 
patients proceed directly to chemotherapy in combination with Trastuzumab. (61)     
Conclusion 
A robust strategy for determining optimal treatment strategies for HER2 positive breast 
cancer as a unique disease is essential.  Laboratory and clinical data point towards HER2 
blockade being a critical drug treatment for most patients with HER2 positive disease. The 
limited clinical trial data to date do suggest, in a manner not dissimilar to what is seen with 
sequential endocrine agents and ER-positive breast cancer, that the development of 
resistance to one anti-HER2 agent, Trastuzumab, does not preclude benefit from further 
anti-HER2 blockade, but the optimum strategy and true level of benefit remain unclear.  In 
the adjuvant setting, Lapatinib is the next in line for testing in HER2 positive early breast 
cancer.  The ALLTO study - a very large multinational trial designed to assess Lapatinib and 
Trastuzumab, each alone, concurrently and sequentially - will confirm or refute the value of 
this approach.  Ensuring maximum patient benefit by optimising the treatment of this disease 
with effective anti-HER2 blockade as the backbone of patient’s therapy should remain high 
on the list of current research priorities.   
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